Standout Papers

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib:... 2012 2026 2016 2021 417
  1. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial (2012)
    Jeffrey R. Infante, Leslie A. Fecher et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 8 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Hallmarks of aging: An expanding universe
2023 Standout
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
2 intermediate papers

Works of Gail Eckhardt being referenced

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
2012 Standout
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
2000

Author Peers

Author Last Decade Papers Cites
Gail Eckhardt 839 885 270 314 20 1.6k
David Wu 1043 861 349 244 11 1.8k
A. K. El-Naggar 692 695 218 231 24 1.5k
M Wada 876 902 362 233 19 1.6k
Torbjörn Norberg 967 814 479 258 17 1.6k
J H Pierce 1453 1004 269 218 23 2.2k
Linda Kapusta 891 1097 400 235 23 2.0k
Jiri Bartek 1507 1421 251 262 15 2.1k
You Hong Fan 784 828 289 171 24 1.7k
Kohta Toshimitsu 614 1127 424 175 11 1.7k
Jack A. Roth 1087 897 199 721 27 1.9k

All Works

Loading papers...

Rankless by CCL
2026